Abbott Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Abbott Laboratories has a total shareholder equity of $39.6B and total debt of $14.8B, which brings its debt-to-equity ratio to 37.5%. Its total assets and total liabilities are $73.0B and $33.5B respectively. Abbott Laboratories's EBIT is $7.3B making its interest coverage ratio 28.4. It has cash and short-term investments of $7.2B.
Key information
37.5%
Debt to equity ratio
US$14.85b
Debt
| Interest coverage ratio | 28.4x |
| Cash | US$7.22b |
| Equity | US$39.56b |
| Total liabilities | US$33.46b |
| Total assets | US$73.02b |
Recent financial health updates
These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01
Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29Recent updates
Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King
Dec 28Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Dec 27Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
Dec 03Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market
Nov 26Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
Nov 01Financial Position Analysis
Short Term Liabilities: ABT's short term assets ($23.1B) exceed its short term liabilities ($13.8B).
Long Term Liabilities: ABT's short term assets ($23.1B) exceed its long term liabilities ($19.7B).
Debt to Equity History and Analysis
Debt Level: ABT's net debt to equity ratio (19.3%) is considered satisfactory.
Reducing Debt: ABT's debt to equity ratio has reduced from 60.2% to 37.5% over the past 5 years.
Debt Coverage: ABT's debt is well covered by operating cash flow (53.2%).
Interest Coverage: ABT's interest payments on its debt are well covered by EBIT (28.4x coverage).